A phase I open label, non-randomized, dose-escalation, multi-center, therapeutic trial of the safety, immunogenicity and efficacy of GI-4000, an inactivated recombinant Saccharomyces cerevisiae immunotherapeutic expressing three different mutations of the Ras oncoprotein, in patients with solid tumors expressing mutations in Ras
Phase of Trial: Phase I
Latest Information Update: 22 Dec 2005
At a glance
- Drugs GI 4000 (Primary)
- Indications Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer
- Focus Adverse reactions
- 22 Dec 2005 New trial record.